WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infection

Journal of Virology

Volumn 82, Issue 1, 2008, Pages 471-486

  Alvarez, R ^a   Reading, J ^a   King, D F L ^a   Hayes, M ^a   Easterbrook, P ^a   Farzaneh, F ^a   Ressler, S ^b   Yang, F ^b   Rowley, D ^b   Vyakarnam, A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CD45RO ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; PROTEIN PS20; PROTEIN WFDC1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL ADHESION; CONTROLLED STUDY; EX VIVO STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; IN VITRO STUDY; MEMORY T LYMPHOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION; PROTEIN STABILITY; VIRUS ENTRY;

CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; GENE SILENCING; HIV-1; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; PROTEINS; T-LYMPHOCYTE SUBSETS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 37349090747     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.00939-07     Document Type: Article

References (51)

1. Alfano, M., and G. Poli. 2005. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol. Immunol. 42:161-182.
2. Ashcroft, G. S., K. Lei, W. Jin, G. Longenecker, A. B. Kulkarni, T. Greenwell-Wild, H. Hale-Donze, G. McGrady, X. Y. Song, and S. M. Wahl. 2000. Secretory leukocyte protease inhibitor mediates non-redundant functions necessary for normal wound healing. Nat. Med. 6:1147-1153.
3. Bas, A., G. Forsberg, S. Hammarstrom, and M. L. Hammarstrom. 2004. Utility of the housekeeping genes 18S rRNA, beta-actin and glyceraldehyde-3- phosphate-dehydrogenase for normalization in real-time quantitative reverse transcriptase-polymerase chain reaction analysis of gene expression in human T lymphocytes. Scand. J. Immunol. 59:566-573.
4. Boaz, M. J., A. Waters, S. Murad, P. J. Easterbrook, and A. Vyakarnam. 2002. Presence of HIV-1 Gag-specific IFN-gamma+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J. Immunol. 169:6376-6385.
5. Bouchard, D., D. Morisset, Y. Bourbonnais, and G. M. Tremblay. 2006. Proteins with whey-acidic-protein motifs and cancer. Lancet Oncol. 7:167-174.
6. Brenchley, J. M., B. J. Hill, D. R. Ambrozak, D. A. Price, F. J. Guenaga, J. P. Casazza, J. Kuruppu, S. A. Migueles, M. Connors, M. Roederer, D. C. Douek, and R. A. Koup. 2004. T-cell subsets that harbor human immunodeficiency virus (HIV) in vivo: implications for HIV pathogenesis. J. Virol. 78:1160-1168.
7. + T cells in vivo. J. Virol. 80:6801-6809.
8. Brenchley, J. M., T. W. Schacker, L. E. Ruff, D. A. Price, J. H. Taylor, G. J. Beilman, P. L. Nguyen, A. Khoruts, M. Larson, A. T. Haase, and D. C. Douek. 2004. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J. Exp. Med. 200:749-759.
9. Bristow, C. L., D. R. Mercatante, and R. Kole. 2003. HIV-1 preferentially binds receptors co-patched with cell-surface elastase. Blood 102:4479-4486.
10. Butera, S. T., T. L. Pisell, K. Limpakarnjanarat, N. L. Young, T. W. Hodge, T. D. Mastro, and T. M. Folks. 2001. Production of a novel viral suppressive activity associated with resistance to infection among female sex workers exposed to HIV type 1. AIDS Res. Hum. Retrovir. 17:735-744.
11. Chang, T. L., and M. E. Klotman. 2004. Defensins: natural anti-HIV peptides. AIDS Rev. 6:161-168.
12. Chen, K., J. Huang, C. Zhang, S. Huang, G. Nunnari, F. X. Wang, X. Tong, L. Gao, K. Nikisher, and H. Zhang. 2006. Alpha interferon potently enhances the anti-human immunodeficiency virus type 1 activity of APOBEC3G in resting primary CD4 T cells. J. Virol. 80:7645-7657.
13. Chen, T. R. 1992. Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility. J. Natl. Cancer Inst. 84:1922-1926.
14. Chertova, E., O. Chertov, L. V. Coren, J. D. Roser, C. M. Trubey, J. W. Bess, Jr., R. C. Sowder II, E. Barsov, B. L. Hood, R J. Fisher, K. Nagashima, T. P. Conrads, T. D. Veenstra, J. D. Lifson, and D. E. Ott. 2006. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J. Virol. 80:9039-9052.
15. Chimpanzee Sequencing and Analysis Consortium. 2005. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 437:69-87.
16. Cicala, C., J. Arthos, E. Martinelli, N. Censoplano, C. C. Cruz, E. Chung, S. M. Selig, D. Van Ryk, J. Yang, S. Jagannatha, T. W. Chun, P. Ren, R. A. Lempicki, and A. S. Fauci. 2006. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells. Proc. Natl. Acad. Sci. USA 103:3746-3751.
17. Ciuffi, A., G. Bleiber, M. Munoz, R. Martinez, C. Loeuillet, M. Rehr, M. Fischer, H. F. Gunthard, A. Oxenius, P. Meylan, S. Bonhoeffer, D. Trono, and A. Telenti. 2004. Entry and transcription as key determinants of differences in CD4 T-cell permissiveness to human immunodeficiency virus type 1 infection. J. Virol. 78:10747-10754.
18. De Souza, A. J., T. B. Oriss, K. J. O'Malley, A. Ray, and L. P. Kane. 2005. T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc. Natl Acad. Sci. USA 102:17113-17118.
19. DeVico, A. L., and R. C. Gallo. 2004. Control of HIV-1 infection by soluble factors of the immune response. Nat. Rev. Microbiol. 2:401-415.
20. Doumas, S., A. Kolokotronis, and P. Stefanopoulos. 2005. Anti-inflammatory and antimicrobial roles of secretory leukocyte protease inhibitor. Infect. Immun. 73:1271-1274.
21. Easterbrook, P. J. 1999. Long-term non-progression in HIV infection: definitions and epidemiological issues. J. Infect. 38:71-73.
22. Farquhar, C., T. C. Van Cott, D. A. Mbori-Ngacha, L. Horani, R. K. Bosire, J. K. Kreiss, B. A. Richardson, and G. C. John-Stewart. 2002. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. J. Infect. Dis. 186:1173-1176.
23. Galli, G., F. Annunziato, C. Mavilia, P. Romagnani, L. Cosmi, R. Manetti, C. Pupilli, E. Maggi, and S. Romagnani. 1998. Enhanced HIV expression during Th2-oriented responses explained by the opposite regulatory effect of IL-4 and IFN-gamma of fusin/CXCR4. Eur. J. Immunol. 28:3281-3290.
24. Goff, S. P. 2004. Retrovirus restriction factors. Mol. Cell 16:849-859.
25. Groot, F., R. W. Sanders, O. Ter Brake, K. Nazmi, E. C. Veerman, J. G. Bolscher, and B. Berkhout. 2006. Histatin 5-derived peptide with improved fungicidal properties enhances human immunodeficiency virus type 1 replication by promoting viral entry. J. Virol. 80:9236-9243.
26. Harari, A., V. Dutoit, C. Cellerai, P. A. Bart, R. A. Du Pasquier, and G. Pantaleo. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254.
27. Hiemstra, P. S., B. A. Fernie-King, J. McMichael, P. J. Lachmann, and J. M. Sallenave. 2004. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. Curr. Pharm. Des. 10:2891-2905.
28. Jana, N. K., L. R. Gray, and D. C. Shugars. 2005. Human immunodeficiency virus type 1 stimulates the expression and production of secretory leukocyte protease inhibitor (SLPI) in oral epithelial cells: a role for SLPI in innate mucosal immunity. J. Virol. 79:6432-6440.
29. King, D. F. L. 2005. PhD thesis. University of London, London, United Kingdom.
30. Kreisberg, J. F., W. Yonemoto, and W. C. Greene. 2006. Endogenous factors enhance HIV infection of tissue naive CD4 T cells by stimulating high molecular mass APOBEC3G complex formation. J. Exp. Med. 203:865-870.
31. Lachmann, P. J. 2002. Microbial subversion of the immune response. Proc. Natl. Acad. Sci. USA 99:8461-8462.
32. Larsen, M., S. J. Ressler, M. J. Gerdes, B. Lu, M. Byron, J. B. Lawrence, and D. R. Rowley. 2000. The WFDC1 gene encoding ps20 localizes to 16q24, a region of LOH in multiple cancers. Mamm. Genome 11:767-773.
33. Larsen, M., S. J. Ressler, B. Lu, M. J. Gerdes, L. McBride, T. D. Dang, and D. R. Rowley. 1998. Molecular cloning and expression of ps20 growth inhibitor. A novel WAP-type "four-disulfide core" domain protein expressed in smooth muscle. J. Biol. Chem. 273:4574-4584.
34. Ma, G., T. Greenwell-Wild, K. Lei, W. Jin, J. Swisher, N. Hardegen, C. T. Wild, and S. M. Wahl. 2004. Secretory leukocyte protease inhibitor binds to annexin II, a cofactor for macrophage HIV-1 infection. J. Exp. Med. 200:1337-1346.
35. McAlhany, S. J., S. J. Ressler, M. Larsen, J. A. Tuxhorn, F. Yang, T. D. Dang, and D. R. Rowley. 2003. Promotion of angiogenesis by ps20 in the differential reactive stroma prostate cancer xenograft model. Cancer Res. 63:5859-5865.
36. McNeely, T. B., D. C. Shugars, M. Rosendahl, C. Tucker, S. P. Eisenberg, and S. M. Wahl. 1997. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. Blood 90:1141-1149.
37. Nishimura, Y., T. Igarashi, O. K. Donau, A. Buckler-White, C. Buckler, B. A. Latent, R. M. Goekem, S. Goldstein, V. M. Hirsch, and M. A. Martin. 2004. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc. Natl. Acad. Sci. USA 101:12324-12329.
38. Ranganathan, S., K. J. Simpson, D. C. Shaw, and K. R. Nicholas. 1999. The whey acidic protein family: a new signature motif and three-dimensional structure by comparative modeling. J. Mol. Graph Model. 17:106-113.
39. Riley, J. L., R. G. Carroll, B. L. Levine, W. Bernstein, D. C. St Louis, O. S. Weislow, and C. H. June. 1997. Intrinsic resistance to T cell infection with HIV type 1 induced by CD28 co-stimulation. J. Immunol. 158:5545-5553.
40. Robichaud, G. A., B. Barbeau, J.-F. Fortin, D. M. Rothstein, and M. J. Tremblay. 2002. Nuclear factor of activated T cells is a driving force for preferential productive HIV-1 infection of CD45RO-expressing CD4+ T cells. J. Biol. Chem. 277:23733-23741.
41. Rowley, D. R., T. D. Dang, M. Larsen, M. J. Gerdes, L. McBride, and B. Lu. 1995. Purification of a novel protein (ps20) from urogenital sinus mesenchymal cells with growth inhibitory properties in vitro. J. Biol. Chem. 270:22058-22065.
42. Schaeffer, E., V. B. Soros, and W. C. Greene. 2004. Compensatory link between fusion and endocytosis of human immunodeficiency virus type 1 in human CD4 T lymphocytes. J. Virol. 78:1375-1383.
43. Sheehy, A. M., N. C. Gaddis, J. D. Choi, and M. H. Malim. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-650.
44. Stevenson, M. 2003. HIV-1 pathogenesis. Nat. Med. 9:853-860.
45. + T cells by human immunodeficiency virus type 1. J. Virol. 79:13714-13724.
46. Von Lindern, J. J., D. Rojo, K. Grovit-Ferbas, C. Yeramian, C. Deng, G. Herbein, M. R. Ferguson, T. C. Pappas, J. M. Decker, A. Singh, R. G. Collman, and W. A. O'Brien. 2003. Potential role for CD63 in CCR5-mediated human immunodeficiency virus type 1 infection of macrophages. J. Virol. 77:3624-3633.
47. Vyakarnam, A., J. Eyeson, I. Teo, M. Zuckerman, K. Babaahmady, H. Schuitemaker, S. Shaunak, T. Rostron, S. Rowland-Jones, G. Simmons, and P. Clapham. 2001. Evidence for post-entry barrier to R5 HIV-1 infection of CD4 memory cells. AIDS 15:1613-1626.
48. Vyakarnam, A., P. M. Matear, S. J. Martin, and M. Wagstaff. 1995. Th1 cells specific for HIV-1 gag p24 Gag are less efficient than Th0 cells in supporting HIV replication, and inhibit virus replication in Th0 cells. Immunology 86:85-96.
49. Wahl, S. M., T. Greenwell-Wild, and N. Vazquez. 2006. HIV accomplices and adversaries in macrophage infection. J. Leukoc. Biol. 80:973-983.
50. Wallace, D. L., P. M. Matear, D. C. Davies, R. Hicks, C. Lebosse, J. Eyeson, P. C. Beverley, and A. Vyakarnam. 2000. CD7 expression distinguishes subsets of CD4(+) T cells with distinct functional properties and ability to support replication of HIV-1. Eur. J. Immunol. 30:577-585.
51. + cells and overexpression of CTLA-4 are linked to loss of antigen-specific CD4 T cells during primary human immunodeficiency virus type 1 infection. J. Virol. 80:10162-10172.